News, Links and Commentary
Saturday, November 15, 2003
Two New Drug Treatments for Wet AMD Show Promise
Two companies are working towards treatments that will prevent the growth of new blood vessels in the back of the eye that cause vision loss in people with wet age-related macular degeneration ('Hope's on the horizon for macular disease', Los Angeles Times, November 10, 2003). Eyetech recently finished trials of a drug called Macugen (pegaptanib sodium) while Genentech's Lucentis (ranibizumab) is in the final phase of trials. Both drugs affect vascular endothelial growth factor (VEGF), a protein which stimulates the growth of blood vessels under the macula.
UPDATE: Eyetech announced results from its clinical trials of Macugen at the American Academy of Ophthalmology meeting over the weekend, according to the New York Times ('Drug Shows Some Promise Against Vision Loss', November 16, 2003). The New York Times article also mentioned another drug that is hoped to benefit people with wet-form macular degeneration. The drug is Texan company Alcon Inc's Retaane.
UPDATE: Eyetech announced results from its clinical trials of Macugen at the American Academy of Ophthalmology meeting over the weekend, according to the New York Times ('Drug Shows Some Promise Against Vision Loss', November 16, 2003). The New York Times article also mentioned another drug that is hoped to benefit people with wet-form macular degeneration. The drug is Texan company Alcon Inc's Retaane.
Comments:
Post a Comment
